These critical effect levels are based on either acute or chronic effects and are usually determined on the 52 basis of results obtained from animal experiments. After applying uncertainty factors to account for 53 differences in sensitivity between species (e.g., animal to man) and within the human population, the critical 54 effect levels are translated to health-based guidance values such as acceptable daily intake (ADI), tolerable 55 daily intake (TDI) or acute reference dose (ARfD) (IPCS, 2010) . In exposure assessment of the chemical 56 substance, the exposure from food is estimated by use of accurate and representative data of relevant food 57 consumption and occurrence of chemical substances in the foods. The last step, risk characterisation, 58
integrates the outcomes of the hazard characterisation and the exposure assessment, and the output is 59
given to the risk managers. 60
Microbiological risk assessment has mainly been used for bacterial pathogens, but it has also been applied 61 to viruses and parasites. It was developed after chemical risk assessment was established and adopted 62 much of the terminology. However, the nature of microorganisms has led to specific challenges, which 63 resulted in some essential differences in the definitions (see Section 2.1), as well as in the risk assessment 64 methodology (Lammerding, 2013) . 65
First, the definition and identification of the microbiological hazard are complicated by the fact that 66 microorganisms adapt and evolve over time, so new strains can emerge with different characteristics than 67 those that were originally described. Next, the dose-response relation typically describes acute health 68 effects, with the probability of acute illness being described as a function of the ingested dose in a single 69 meal. Due to the differences in responses between humans and animals, data for microbiological dose-70 response models can usually not be derived from animal experiments. As an alternative, human data are 71 required, but these are not easily obtained. The use of biologically plausible "single hit" models that assume 72 that, with low probability, a single bacterial cell can lead to illness, is a general practice in microbiological 73 dose-response modelling (Haas et al., 2014; FAO/WHO, 2003) . Exposure assessment is complicated by the 74 fact that living organisms can multiply, and consequently, the occurrence of microbial growth and inactivation 75 imply that concentrations can change during food processing and storage. Therefore, concentration data 76 alone are insufficient and the ingested doses have to be estimated by means of mathematical modelling in 77 so called "process risk models" that apply predictive models for growth and inactivation (FAO/WHO, 2008; 78 Zwietering & Nauta, 2007) . Note that this implies that, in contrast to chemicals, exposure depends on the 79 growth and inactivation characteristics of the microorganism of concern (Figure 2). Critical limits for the 80 presence of microorganisms are generally not determined on the basis of the hazard characterization only, 81 so equivalents of NOAEL and BMD as used in toxicology are not applied. Instead, risk-based microbiological 82 targets such as food safety objective (FSO) are used, which are derived from risk characterization, i.e., a 83 combination of hazard characterisation and exposure assessment (FAO/WHO, 2006b). 84
Risk assessment of essential nutrients follows the same principles as chemical risk assessment, with the 85 notion that essential nutrients have a dual risk relationship with risks occurring at both the upper end 86 ('excess') and lower end ('deficiency') of the intake range (NCM, 2014) . Another distinct feature is that data 87 M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 4 on adverse effects in relation to excessive or deficient amounts of nutrients are often available from human 88 studies, which compared with chemical risk assessments overall, may reduce the size of uncertainty factors 89 applied. The tolerable upper intake level (UL) is the maximum level of chronic daily nutrient intake from all 90 sources judged to be unlikely to pose a risk of adverse health effects to humans (EFSA, 2006) and thus 91 includes an uncertainty factor as in the case of chemicals. The lower threshold intake (LTI) is the level of 92 intake below which, on the basis of current knowledge, almost all individuals will be unable to maintain 93 "metabolic integrity", according to the criterion chosen for each nutrient (EFSA, 2010b) . 94
Consideration of specific nutrient intakes associated with adverse health effects above or below specific 95 intake levels has received less attention in the nutrition area compared with non-nutrients, such as drugs, 96 food additives, and pesticides (IOM, 2007) . The concept of the risk assessment of nutrients was stimulated 97 by the IPCS in 2002 (IPCS, 2004) , and by the Codex Alimentarius, FAO/WHO, EFSA and others 98 (FAO/WHO, 2006c; Aggett, 2010; Taylor & Yetley, 2008) . In addition, the implementation of an organized 99 nutritional risk assessment approach for scientific reviews has been stimulated by the increased use of food 100 supplements, fortified-and functional foods and subsequent requests by regulatory agencies to identify 101 upper levels of nutrient intake (Taylor & Yetley, 2008; Taylor, 2007) . In 2010, EFSA published a scientific 102 opinion on the general principles for development and application of dietary reference values (DRVs) (EFSA, 103 2010b), and other DRV processes have followed the same risk assessment approach, including the update 104 of the Nordic Nutrition Recommendations (NCM, 2014). 105 Current approaches thus predict a threshold above which the nutrient intake is excessive, and another 106 threshold below which the intake is inadequate, while an intake range between these two boundaries can be 107 considered an 'optimal' intake range within which the recommended intake and the benefit assessment is set 108 (NCM, 2014). Nutritional benefit assessment may thus be considered as the intake range beyond which 109 there is a risk. Nutritional RBA can be broadened to not only consider nutrients, but also to include any 110 excess or deficient intake of foods, diets or energy. 111
One example of the application of benefit analyses is the European health claim regulation, which states that 112 health claims should be "substantiated by generally accepted scientific evidence and by taking into account 113 the totality of the available scientific data, and by weighing the evidence" (EU Commission, 2006). The steps 114 involved in the assessment of health claims include identification and characterization of the food or the food 115 compound, definition of the effect and assessment of whether such an effect can be considered beneficial to 116 human health. Finally, the scientific substantiation for a beneficial effect is assessed based on the totality of 117 the current evidence between the consumption of the food or the food compound and the claimed effect 118 studied in the appropriate target group (EU Commission, 2006) . 119 A comparison of the application of risk and benefit assessment for chemical substances, microorganisms 120 and nutrients shows that, traditionally, risks are considered for all, but benefits only in nutrition. An essential 121 difference between different types of risk and benefit assessment is illustrated in Figure 3 . Typically, looking 122 at both acute and chronic adverse effects, chemical and microbiological risk assessments investigate 123 situations where exposure is to be considered "too high". This implies that the risk increases with higher M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 5 doses, and threshold doses may be derived as cut-off points below which the intake is considered safe, or 125 the associated risk is considered acceptable (Barlow et al., 2015) . In contrast, within nutrition, both the 126 situation where there is a risk of nutritional deficiency and the situation where there is a risk of nutrient 127 intoxication are relevant, creating a "window of benefit" (Palou et al., 2009; Tijhuis et al., 2012) ). Interestingly, 128 research in situations where the intake is too high (above the upper intake level (UL)) is commonly referred 129 to as toxicology, whereas research considering beneficial intake or too low intake, is part of nutrition. 130 1.2 The development of risk-benefit assessment 131 Although independent risk and benefit assessments have proven to be useful for decision support in food 132 safety and nutrition, their results may be too much focused on one hazard, one food compound or one health 133 effect. When establishing guidelines and advice on food consumption, nutrient intake and diet choices, there 134 is a need for an overarching approach, in which all of the relevant health risks and benefits are included and 135 compared. This need for RBAs has been identified earlier in several publications ( EFSA, 2007; EFSA, 136 2010a; Renwick et al., 2004 ) and led to the development of RBA of foods as a new research discipline. An 137 RBA is multidisciplinary by nature, and may require expertise from not only toxicologists, microbiologists, and 138 nutritionists, but also from epidemiologists, chemists, librarians, statisticians, and medical scientists. As 139 proposed in the EU-funded project BRAFO (Benefit-Risk Analysis of FOods) (Boobis et al., 2013) , it is 140 common to use the risk analysis and risk assessment frameworks (Figures 1 and 2) as the basis for the RBA 141 methodology by applying the established concepts to both risks and benefits. A recent extensive review of 142 studies related to the combined RBA of foods, nutrients and compounds shows that the majority of published 143 studies have been related to fish consumption where the nutritional beneficial effects are compared with the 144 adverse effects from chemicals (Boué et al., 2015) . This RBA of fish (e.g. (Hoekstra, Hart, et al., 2013) ) is an 145 example of an RBA case where the content of polyunsaturated fatty acids, and in particular 146 docosahexaenoic (DHA), and eicosapentaenoic fatty acids (EPA), recognized for their health benefits, is 147 counterbalanced by the content of pollutants such as methylmercury and dioxins, known to potentially induce 148 adverse health effects. There is also an example of microbiological aspects being added to an RBA of fish 149 (Berjia et al., 2012) . The basis is that a number of tiers have to be evaluated before making a decision on the required steps to 155 be taken in the RBA. This approach proposes that a qualitative assessment is sufficient if data are scarce or 156 there is clear evidence that risks outweigh the benefits (or vice versa). If the balance between benefits and 157 risks is unclear, the assessment has to be performed at a higher tier, including quantitative assessment. As Although significant progress has been made in the development of methods and terminology in RBA, 164 several challenges remain. Some of these challenges relate to the differences between the underlying 165 research disciplines, which have different use of terminology and different approaches for the assessment of 166 health effects related to the consumption of food. Other challenges relate to the specific objective of RBAs, 167 the scarcity of the required data, or the complexity of the characterization of health effects. Below, we 168 provide a description of ten major challenges that were identified during the course of working with RBAs, 169 with explanations of the challenges and discussion on the way forward for meeting them in the future. 170
Definitions 171
The different approaches used in the disciplines contributing to RBA (Section 1.1) apply different terminology 172 or may apply the same terminology in a different way. Dissimilar definitions can lead to confusion and lack of 173 understanding of the risk-benefit question (Section 2.3). As an example, the central concept of "hazard" is 174 defined differently in various contexts. Published definitions of hazard include "inherent property of an agent 175 or situation having the potential to cause adverse effects when an organism, system, or (sub)population is 176 exposed to that agent" (IPCS, 2004), "the potential of a risk source to cause an adverse effect(s)/event(s)" 177 (Renwick et al., 2003) and "a biological, chemical or physical agent in, or condition of, food with the potential 178 to cause an adverse health effect" (CAC, 2011). In the latter definition, the hazard is the agent (or risk 179 source, that is the pathogen, chemical substance or food compound) and in the others it is an inherent 180 property or the potential of this agent. Due to this difference in definitions, the hazard is usually synonymous 181 to the pathogen(s) of concern in microbiological risk assessment, whereas it usually is the potential health 182 effect caused by the chemical substance or food compound in chemical risk assessment and nutrition 183 (Barlow et al., 2015) . 184
Similarly, there are different definitions of "risk", for example "the probability of an adverse effect in an 185 organism, system, or (sub)population in reaction to exposure to an agent" (IPCS, 2004; EFSA, 2010a), or "a 186 function of the probability of an adverse health effect and the severity of that effect, consequential to a 187 hazard(s) in food" (CAC, 2011). So in one definition the risk is a probability, in the other, it is a combination of 188 probability and severity. 189
When mirroring risk assessment to benefit assessment, the benefit is defined at a level comparable to both 190 the hazard and the risk (EFSA, 2006; Boobis et al., 2013), so "benefit" is both the counterpart of "hazard" 191 and the counterpart of "risk". Hence, the term "benefit" can be used for anything between the agent causing 192 the health effect and the probability and magnitude of that effect. Moreover, when used as equivalent of 193 "risk", the benefit is not necessarily interpreted as the probability of a positive effect, but commonly as the 194 The present definitions can be well understood in a historical perspective, given that RBA has evolved from a 197 variety of disciplines. However, for further development, the discipline "risk-benefit assessment of foods" 198 needs a clearer set of definitions and harmonized terminology that is comprehensible for all those involved. 199
To accommodate the fact that some agents or food compounds (i.e. "hazards" of "benefits") can be both a 200 source of positive and negative health effect depending on the exposure (Figure 3 In this paper, we distinguish between two overall approaches to assess health effects in RBA and refer to 209 them as "bottom-up" and "top-down". This terminology is derived from studies in microbiological food safety 210 aimed at ranking microbiological food risks (EFSA, 2015; Cassini et al., 2016). The two approaches are 211 characterised by their different starting point. The typical risk assessment approach, which starts with the 212 hazard identification for the food product or its ingredients and finishes with the human health outcome 213 obtained after combining the exposure assessment with a dose-response model (Figure 2 ), is referred to as 214 the bottom-up approach. The alternative top-down approach starts with the adverse (or beneficial) health 215 outcomes as obtained from human observational studies, i.e., incidence data and identified risk factors. 216
These are then traced back to the food sources that caused the disease of concern (or benefit of desire), 217 thus linking the health effect to the food product. 218 A similar distinction in approaches can be made in nutritional and chemical risk assessment. The usual risk 219 assessment approach (i.e., bottom -up) is targeted at intake of specific nutrients or food compounds, and 220 the dose-response relation is typically derived from animal experimental data. The alternative top-down 221 approach is an approach where relative risk estimates from human observational studies are used and 222 linked to foods or food compounds that are identified as risk factors. In the review of the BRAFO project, 223
Boobis et al. (2013) identify these two approaches as one based on experimental animal data (bottom-up) 224
and one based on human observational studies (top-down). We prefer the bottom-up and top-down 225 terminology as it is more generic and can also be applied for microbiological risk assessment, which does 226 not apply animal data. 227 Hence, with the bottom-up approach, the assessment starts with the food product, food compound or 228 contaminant, followed by an exposure assessment and a dose-response model used for the risk-benefit 229 characterization. An advantage of this approach is a direct causal link between intake of the food product or 230
food compound (or contaminant) of concern and the associated health effect. A disadvantage is that there 231 may be a large uncertainty attending the exposure assessment and (especially) the dose-response. 232
With a top-down approach, the starting point of the analysis is the incidence of a health outcome in the 233 consumer. Typically, data from epidemiological studies (case-control studies, cohort studies, randomized 234 controlled trials) are used to associate human health outcomes with risk factors that are defined in terms of 235 food consumption, allowing for the estimation of metrics such as the odds ratio or the relative risk. These 236 measures of association are then combined with population statistics and incidence data to estimate the 237 actual health risks in the population. The relative risks may also be used to construct a dose-response 238 relation, where the relative risk is a function of the intake as specified in the underlying study. The strength of 239 human observational studies is that they are based on actual health effects, measured in specified 240 populations. Weaknesses are that the observed associations are not a proof of causation, that the studied 241 population may not be representative for the population group of interest and that many data are required if 242 the health effect of interest is small. For microbial pathogens, a top-down approach can be used to estimate 243 the number of cases of disease caused by a pathogen due to its presence in a specific food, a method 244 referred to as "source attribution" (Pires et al., 2009 ). Here incidence data on a specific health outcome (e.g., 245
gastroenteritis caused by salmonellosis) is traced back to a specific food source (e.g., chicken meat) by the 246 use of subtyping information of isolates of the pathogen in human cases and food sources. 247
Generally, within RBA, it is necessary to use different approaches for different health effects of food 248 compounds or contaminants. are derived from bottom-up approaches. The reason for the application of these different approaches is 252 obviously the availability of data, which in turn is related to the feasibility of acquiring the requested data and 253 also the quality of the studies providing the data. Still, if different approaches are used to obtain different 254 heath effect estimates in the same RBA, it may be hard to compare them. Not only can there be a difference 255 in the known bias associated with the approach (such as a potential to overestimate the risk obtained from 256 dose-response models derived from animal experiments), but also the nature of the uncertainties associated 257 with the assumptions of the approaches will be different (Section 2.5). uncertainties. They found that the difference in the point estimates of the risks as found by the different 262 approaches can be large, but they still have overlapping uncertainty intervals. This implies that one cannot a 263 priori conclude that one approach is better than the other. It is advisable to aim for evidence synthesis by generally a comparison between two, or a series of, choices, alternative policies or courses of action, 272 described in the form of scenarios (Boobis et al., 2013) . In these scenarios, both positive and negative health 273 effects have to be taken into consideration. When a series of scenarios is compared, the risk-benefit 274 question can be used to identify the optimum intake (Berjia et al., 2014 ). An aim of the risk-benefit question 275 is to specify the RBA-task in such a way that it is feasible and will provide useful results. For example, an 276 RBA of fish should indicate what sort of fish (e.g., lean/fatty, farmed/wild), target population group, and in 277 general any other constraint that could narrow the risk-benefit question. In the end, the level of specification 278 of the question will also depend on the data available. 279
As a variety of risk-benefit questions can be asked, it can be helpful to categorise them and to identify 280 specific approaches that can be used to answer these different categories of questions. Here, one type of 281 categorisation is the level of aggregation: the risk-benefit question can be targeted at a food compound level 282 (a nutrient, a chemical or microbiological contaminant), a food product level (e.g., fish) or a diet level 283 (Hoekstra et al., 2008) . 284
When the risk-benefit question is targeted at the food compound level, it should be a compound that is 285 associated with both positive and negative health effects, e.g., a (micro-) nutrient. Examples for RBAs 286 directed at the food compound are those for folic acid ( studies. To assess the total intake of the food compound, it will be necessary to consider the intake of all 290 relevant foods and food products in the diet that contain it, and the concentrations of the compound in these 291 foods and food products have to be known. As this can be rather complicated, one can choose a risk-benefit 292 question that only considers a difference in intake or concentration in one or a few food products, making 293 some assumptions for the background diet. approach may be used where all relevant food compounds (and contaminants) in the food product have to 301 be identified and comprised in the RBA to assure that the health effects of interest are included. In that case, 302 a selection of relevant food compounds and contaminants needs to be made based on the associated levels 303 of evidence and the precise risk-benefit question. However, because in some cases only exposure through
the selected food product is considered, and not the total exposure from all food products containing the 305 compounds, it is difficult to use a bottom-up approach with a dose-response relation for each compound. 306
When considering a whole diet, the bottom-up RBA approach will usually not be feasible, unless the risk-307 benefit question is clearly delimited: the number of food compounds (and contaminants) and their combined 308 intakes easily get too large for a complete exposure assessment and hazard characterisation. However, a 309 top-down approach using studies on human consumption may be possible if the appropriate data are 310 available, for example from a dietary intervention study. Van Kreyl et al., 2006, performed a study to analyse 311 the health effects of the current diet in the Netherlands that may be regarded as an RBA of diets, but 312 otherwise, to our knowledge, no formal RBAs of whole diets have been performed so far. 313
In each of these three categories of risk-benefit questions, the options for inclusion and exclusion of food 314 compounds and contaminants, food products and health effects are large. To clarify the selected elements in 315 the risk-benefit question, we propose the use of schematic framing of the risk-benefit question, as 316 exemplified in Figure 4 for four published risk-benefit studies for food compounds or food products. A 317 scheme like this is broadly applicable and may offer a transparent way to identify different types of risk-318 benefit questions and clarify how the risk-benefit question is addressed. In the case of an RBA of a whole 319 diet, the scheme would be pretty complex, which stresses the difficulty of doing an RBA of a whole diet. 320 2.4 Lack of data and knowledge and the consequential uncertainties 321 The data needs for an RBA are large and diverse. RBAs frequently face data gaps and lack of knowledge, 322 such as lack of human data, information on dose-response and intake levels for specific population groups. 323
These challenges are also faced in other modelling exercises (such as many risk assessments), and need to 324 be addressed by documentation and discussion of the assumptions made. A consequence of limited data 325 and lack of knowledge is that the uncertainty related to the assessment may be large. Yet, characterising 326 this uncertainty is crucial in the risk-benefit characterisation. 327
As part of the QALIBRA project, Hart et al., 2013, provided an overview and discussion on the importance 328 and challenges related to uncertainty in RBA and described strategies to deal with uncertainty. The 329 QALIBRA software tool developed in the project allows the user to perform stochastic RBA and, as part of 330 that, analyse uncertainty, either by quantitative methods or by qualitative scenario analyses. This has been 331 an important step forward for the analysis of uncertainty within RBAs. relationships, this means that the use of BMD models may be preferred over NOAELs and LOAELs, and that 342 the uncertainty factors used to translate animal data to human guidance values may not be appropriate if the 343 dose-response relationship is to be applied in RBAs. 344
The uncertainty attending the dose-response relations for microbial pathogens is also large. These dose-345 response relations are usually based on human volunteer studies or outbreak data, which means they are 346 based on limited data sets, for specific strains and specific population groups, and generalised thereafter. 347
Dose-response relations based on studies with healthy young volunteers may be expected to underestimate 348 the risk, whereas those derived from outbreaks (with more virulent strains) may overestimate the risk. 349
Further, it is known that immunity plays an important role and may lead to overestimation of the risk, but it is 350 difficult to include this in the modelling (Havelaar & Swart, 2014) . Uncertainties are an inevitable intrinsic element of science, risk assessment and RBAs, and it is of utmost 364 importance that they are not ignored. A challenge here is that, as in risk assessment, it is not primarily the 365 objective of an RBA to assure that the uncertainty is small enough (as aiming for a p-value smaller than 366 0.05), but to indicate how large the uncertainty actually is (Nauta, 2007) . One should deal with the identified 367 uncertainties by explicitly addressing and characterizing them in the assessment and by clearly 368 communicating them to all stakeholders. By framing the risk-benefit question ( Figure 4 ) and addressing the 369 required data, RBA models can be important in identifying the most important data gaps and the crucial lack 370 of knowledge. Thus, they can guide future data generation and research. Setting the future research agenda 371 based on the most important sources of uncertainty can therefore be one of the key outputs of an RBA. Another consequence of this discrepancy is that different types and levels of uncertainty will be associated to 387 the risk assessment on the one hand and the benefit assessments on the other, which complicates the 388 characterization of the combined RBA even further (Section 2.4). 389
The imbalance in the required level of scientific evidence for risks and benefits demands a paradigm shift 390 from the RBA as a sum of risk and benefit assessment to the RBA as a well-integrated risk-benefit 391 assessment. Such a well-integrated RBA deals not so much with studying a hypothesis about the presence 392 or absence of a health effect associated with the intake of a (certain amount of) food product or food 393 compound or contaminant, but predominantly with the size of the health effects. Even though the strength of 394 evidence for the presence of a health effect is strongly correlated to the size of the effect, these are not the 395 same thing. Stochastic modelling techniques, which include quantification of uncertainty and variability, allow 396 an evaluation of potential health effects, even if the effects themselves are not statistically significant. In 397 doing so, it may be possible to study how the estimated size of the effect, and some alternative scenarios 398 about these effects, may impact public health. From this, one might conclude that the risk or benefit is not 399 very large, even if the evidence would be convincing, or the opposite, that a risk or benefit may be large, 400 even if the level of evidence is low. Findings like this can indicate crucial data gaps (Section 2.4) and may, in 401 an objective way, help identify where further research is needed. 402
Substitution 403
In general, an RBA compares the health effects of two or more intake scenarios, defined as specified 404 changes in the amount or type of food consumed. As a side effect, these specified changes in intake may 405 also imply a change in the intake of other food products to compensate for the part of the diet that is deleted 406 or added. So far, however, such "substitution" is rarely included in an RBA. The risks and benefits of 407 increasing fish intake are for example frequently studied, but the related decrease in the intake of one or 408 more other foods and the consequential health effects of that decrease are not included in the assessment 409 this context is also that this substitution in terms of alternative amounts and types of food eaten may vary 413 among individuals, adding even more to the complexity of the RBA. 414
Alternatively, it can be that substitution is the specific purpose of the RBA, as for example in the case of food 415 fortification, when a non-fortified food is replaced by a fortified food, and substitution is an inevitable part of 416 the scenarios investigated (Hoekstra et al., 2008) . Likewise, substitution has been investigated in an RBA 417 when added sugar is substituted by artificial sweeteners (Hendriksen et al., 2011; Husøy et al., 2008; 418 Verhagen et al., 2012b) . In the first case, no additional precautions need to be taken, as the fortified and 419 non-fortified diets are similar except for the content of the specific nutrient. In the sugar-artificial sweetener 420 case, the substitution leads to non-isocaloric diets and this may need to be addressed because it implies that 421 the diet may change in more aspects than just the intended substitution. 422
To meet this challenge, it is a prerequisite that substitution is acknowledged in the RBA, either by specifically 423 addressing it in the intake scenarios that are analysed, or by referring to it in the discussion of the 424 assumptions and in the uncertainty characterization. As simplified substitution scenarios, one can consider 425 replacements in the same food groups (e.g. meat and fish) and isocaloric alternatives (to make sure the 426 energy intake stays similar). Next, the impact of substitution can be analysed in separate scenarios, where 427 different options for substitution are compared. be sufficient if it is clear that the risks dominate the benefits or vice versa. If, alternatively, a quantitative 431 approach is applied, the use of one common integrated health metric is needed to combine different positive 432 and negative health effects in an RBA and to compare different health effects within and between 433 assessments. The quantitative metric that is used most in published RBAs of foods is the disability adjusted 434 life years (DALY). The DALY is a measure that indicates how many healthy years of life are lost due to 435 premature death or due to decreased quality of life associated with a disease or hazard (Devleesschauwer et 436 al., 2014; Havelaar et al., 2000; Hoekstra et al., 2008; Murray, 1994) . The quality of life is determined by the 437 duration of illness and a weighing factor that indicates the severity of the specific disease considered 438 (Salomon et al., 2015) . The DALY is increasingly used for risk ranking (Van der Fels et al., 2018) and in 439 burden of disease studies , which aim to compare and prioritise health risks, it is used 440 as an aid to policy makers when they have to decide where to spend their available resources. Methods 441 used and results obtained in these studies are also useful for RBAs because the health effects considered 442 can be the same and a large part of the underlying calculations is similar. 443
The DALY is commonly applied at a population level. Burden of disease, for example, is defined as the sum 444 of individual DALY across the population, and applied as a measurement of the gap between current health 445 status and an ideal health situation where the entire population lives to an advanced age, free of disease and 446 disability (WHO, 2013). As risk-benefit questions are usually targeted at a change of intake scenario within 447 the population (Section 2.3), the DALY is also commonly applied as a population metric in an RBA. However, 448 populations consist of a large variety of individuals with varying food preparation habits, consumption M A N U S C R I P T
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14 patterns and sensitivity to food hazards. When the RBA is done and the risk-benefit balance for the 450 population is interpreted as the risk-benefit balance for the average consumer, this does not mean that this 451 balance is the same for all individual consumers. It can be that the balance goes in different directions for 452 different subpopulations, e.g., the elderly, pregnant women or children, and because there are differences in 453 intake and sensitivity between individuals. Therefore, the variability between consumers has to be taken into 454 consideration, for example by using a stochastic approach (Hart et al., 2013) . 455
Apart from the DALY, other metrics can be used, such as monetary integrated metrics like the cost-of-illness, 456 which aims to calculate the direct and indirect monetary costs to society related to disease and death, or 457 willingness-to-pay, a stated preference method which elicits the resources an individual is willing to give up 458 for a reduction in a specific health risk. We refer to Mangen Reasons for this underrepresentation of microbiology in RBA are probably the intrinsic differences in the 479 underlying research disciplines and the different nature of the associated health effects. Microbiological risks 480 are often linked with mild health effects such as short episodes of gastro enteritis. They can also lead to 481 long-term sequelae and severe chronic effects, but these are typically not registered and less often 482 measured (Havelaar et al., 2012) . In principle, microorganisms can rather easily be eliminated from foods by 483 application of a heating process, which might suggest that microbiological risks from food can quite easily be 484 prevented. However, microbial contamination of food products and exposure are common, and, to some 485 extent, more easily accepted by consumers (Kher et al., 2013) .
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because the availability of the relevant data is larger, the recent World Health Organization (WHO) study on 488 the global burden of foodborne disease is primarily focused on microbiological 489 hazards, and only four chemical substances have been considered in the WHO report. The results suggest 490 that the disease burden related to the exposure to microorganisms may be larger than that for chemicals, but 491 more comparable disease burden estimates for chemical substances are required before an overall 492 comparison between the burden of chemical substances and microbiological pathogens can be made. 493
However, the results confirm that risk associated with microbiological hazards can be quantified and that it is 494 important to include microbiological risks in RBAs as well. 495
The inclusion of microbiological risks and benefits in RBAs requires that the specific characteristics of 496 microbiological agents are acknowledged, and that they are included in case studies. As illustrated by Berjia 497 et al. (2012) microbiological risks can specifically be of importance when the effects of food processing are 498 included in the risk-benefit question, as the doses largely depend on the storage and food preparation. It 499 would therefore be advisable that data on food preparation (such as storage times, temperatures and the 500 applied cooking style) are included in dietary surveys. 501
The challenges from differences in approach between chemical and microbiological risk assessment needs 502 further study to allow the development of a more integrated approach towards RBAs (Sections 1.2 and 2.5). 503
Recently developed tools that are increasingly adapted to allow comparisons between chemical and 504 microbiological health risks (e.g. FDA-iRisk; Chen et al., 2013) can help to address these challenges. 505 2.9 The scope of risk-benefit assessments 506
The scope of a risk-benefit question in relation to food may be much wider than direct health impact and can 507 include socio-economic, psychological and/or environmental dimensions (Boobis et al., 2013) . When 508 consumers select their food, the health effect is only one of the concerns; others include cost, taste, quality 509 and sustainability of the production. An indicated health risk may be counterbalanced by each of these, for 510 example, if low price and good taste are considered benefits that outbalance the health risk. 511
One may consider widening the scope of RBAs of foods and include some of the aspects mentioned above. 512
Cost is an obvious choice, which is an intrinsic part of the RBA when metrics such as the cost-of-illness or 513 willingness-to-pay are used (Section 2.7). It can also be added to the RBA by means of a cost-utility, cost-514 benefit or cost-effectiveness analysis, as for example done for the costs of intervention strategies that aim to 515 lower the public health risks of Campylobacter from broiler meat (Mangen et al., 2007; Van Wagenberg et 516 al., 2016) . Measurements such as the "cost per avoided DALY" can be highly informative for risk-benefit 517 managers because they can indicate the economic consequences of scenarios in RBAs and allow for a 518 comparison of policies. 519
Also, environmental sustainability can be taken into account, for example by the use of life cycle assessment 520 (LCA), a product-oriented environmental assessment tool that provides a systematic way to quantify the 521 environmental effects of individual products or services (Hermansen & Nguyen, 2012) . A methodology is M A N U S C R I P T
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16 being developed to include nutritional health impacts in LCA (Stylianou et al., 2016) , which could clearly 523 contribute to the development of RBAs with a scope beyond immediate health effects of food intakes. 524
Ultimately, it can be attractive to address all of the relevant aspects in one overall analysis, for example by 525 the use of multi criteria decision analysis (MCDA). This method has for example been applied to the 526 prioritisation of foodborne pathogens (Ruzante et al., 2010) , taking into account public health impact 527 (expressed in DALY and cost-of-illness), market impact, consumer perception and acceptance, and social 528 sensitivity to impacts on vulnerable consumer groups and industries. In MCDA, an integrating scoring 529 method is developed, which weighs the importance of different factors that are considered relevant for the 530 decision making, allowing one to come with a final ranking that includes all of these factors. 531
Defining the scope of the RBA is clearly an issue that should be decided upon when the risk-benefit question 532 is formulated. A broader scope includes more relevant issues, but also implies an increasing demand for 533 resources in terms of research efforts, data and method development. Clearly, challenges that complicate 534
RBAs, such as the lack of data and knowledge, and the consequential uncertainties, the imbalance in level 535 of scientific evidence and the use of quantitative metrics, only get more weight when a broader scope is 536
taken. Yet, the ongoing developments show that progress can be made, and with multidisciplinary scientific 537 collaboration and investment in research supporting RBAs, this progress can be strengthened in the future. 538 2.10 The application of risk-benefit assessments 539 So far, several RBAs have been performed, but mainly within research projects that were directed at the 540 development of RBA frameworks and methodology. The aim of these RBAs was primarily to illustrate the 541 potential of the methodology and the risk-benefit question was not posed by independent risk-benefit 542 managers but by the researchers themselves. There is now a need for more experience with the practical 543 application of RBAs and the proposed methodologies. These practical applications of RBAs can fall into two 544 categories: those leading to recommendations or guidelines to food safety and health authorities, and those 545 leading to process and formulation design by industry (Boué et al., 2015) . The first application is the one 546 considered most often and typically the request for such an RBA originates from national or international 547 food and health authorities that have a mandate to advise the public on a particular food or diet and have 548 identified a need to establish a scientific basis for this advice. Examples are an RBA on fish and fish 549 products performed in Norway (Skåre et al., 2015) and an RBA on nuts performed in Denmark (Mejborn et 550 al., 2015) . Another reason for the authorities to make requests for an RBA is a need for an evaluation of 551 health effects of proposed fortification of foods, as for example with vitamin D, folic acid (Hoekstra et al., 552 2008) or iodine (Zimmermann, 2008) . 553
Food producers may have an interest in RBAs when they change their production or the formulation of their 554 products. This is especially of interest when this change is based on a wish to decrease one specific health 555 risk that can go at the expense of another. For example, when a heating step is introduced to decrease 556 microbiological health risks, this can go at the expense of the formation of potentially carcinogenic 557 substances (Havelaar et al., 2000) and/or decreased vitamin levels. In such cases, RBA can be an excellent 558 tool to settle a dispute that cannot be solved on the basis of the identification of risks and benefits alone. This is important to assure the scientific quality, to increase the experience in the research community and to 565 aid the international discussion on the potential and challenges of RBAs. 566
Conclusion

567
RBA is an evolving discipline in food safety and nutrition that takes advantage of achievements in a variety of 568 underlying disciplines. As it integrates various health concerns, it is a valuable method to estimate the overall 569 health effects related to food consumption and diet choice, which can be applied both by food and health 570 authorities and the food industry. Recognizing the progress that has been made in the past decade and 571 based on previous work, we have identified a series of challenges that should be met to develop the area 572
further and indicated steps that should be taken for further progress. The challenges and suggested ways 573 forward in meeting them are summarized in Table 1 . 574
To meet the challenges of RBA, it is important that researchers in underlying disciplines and stakeholders in 575 food regulation, production, retail and consumption from different regions in the world agree on definitions 576 and concepts that are practical and agreeable for all. Based on relevant risk-benefit questions, a series of 577 risk-benefit studies should be performed, not so much to develop methods, but predominantly to identify the 578 practical challenges that are met when working on RBA case studies. When investigating these practical 579 challenges, steps can be made in categorizing them and in developing and harmonising agreeable methods 580 to address them. 581
For the future development of the RBA area, it is important to perform methodological research into some of 582 the identified challenges because they cannot be met by performing case studies alone. Examples are 583 studies into the differences and similarities in results obtained from top-down compared with bottom-up 584 approaches (by the application of comparative analytical tools and simulation studies), research into 585 uncertainty analysis and comparative studies on integrated health metrics and metrics outside the health 586 domain. Additionally, risk communication is one of the key pillars in risk analysis and should also be an 587 inherent part of RBAs of foods, particularly for the communication of quantitative metrics and their attending 588 uncertainties to all stakeholders. 589
Overall, with an increasing demand from different stakeholders for holistic and objective assessments of the 590 health effect of foods, multidisciplinary RBA is a promising research area for the future. Impressive progress 591 has been made and, despite the remaining challenges, we expect that more progress will be made in the 592 next decade. The steps forward proposed in this paper will be useful in taking the research area further, 593 allowing for transparent and reliable RBAs to be performed on a wider scale in the future. the approach used in the three disciplines are explained in the text. Traditionally, the link between hazard 829 identification and exposure assessment is not indicated in toxicology and nutrition, whereas it is essential in 830 microbiology, where exposure depends on the microorganism of concern. 831 Figure 3. A comparison of approaches for hazard characterization used in toxicology and microbiology (left) 832 and nutrition (right). In toxicology and microbiology, the risk increases with the dose; benefits are not defined. 833
In nutrition, intake of a food compound can be too low or too high; intake between these levels ("the window 834 of benefit") is considered beneficial for health. X: Dose with critical response as used in chemical risk 835 assessment (e.g., LOAEL or BMD); no equivalent metric exists in microbiological risk assessment. LTI: 836
Lower threshold intake, intake below this level represents a deficiency; UL: Upper intake level, intake above 837 this level could give a toxic effect. 838 
Imbalance of level of evidence
The level of evidence required for benefits is usually larger than for risks, hence risks are more likely to be included in RBAs.
Put emphasis on the size of the health effect rather than on the presence or absence of the health effect.
Substitution
When an alternative intake scenario implies a change in consumption of one food product, it will have consequences for others. There can be many options for substitution. • Key challenges in risk-benefit assessment of foods are addressed.
• Challenges relate to interdisciplinarity, methods, data, health metrics and applications.
• Suggestions for meeting the identified challenges are discussed.
